Skip to content

Bioventus BVS Proceeds From Long Term Lines Of Credit

Proceeds From Long Term Lines Of Credit at other companies

Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
$64.03M
Enovis logo
EnovisENOV
$72M0.0%
Alphatec Holdings logo
Alphatec HoldingsATEC
$2.75M-32.9%

Other financials

Income statement

See full
Revenue$132.1M+6.6%
Gross profit$90.8M+9.3%
Operating income$8.4M+72.8%
Net income$3.1M+218%
EPS (diluted)$0.04+200%

Balance sheet

See full
Cash & equivalents$35.8M+57.2%
Total debt$288.4M-21.2%
Total equity$188.9M+27.5%
Total assets$650.5M-5.9%

Cash flow

See full
Operating cash flow$8.9M+146%
CapEx$574.0K-30.5%
Free cash flow$8.4M+141%

Valuation

See full
Market cap$659.19M+51.7%
Enterprise value$911.76M+17.2%
P/E23.1×
P/S1.1×+0.4×

Profitability

See full
Gross margin68.7%+1.2pp
Operating margin10%
Net margin4.9%+3.2pp
FCF margin17.5%+13.2pp

Returns & leverage

See full
Return on equity16.9%+10.9pp
Debt / equity1.5×-0.9×
Current ratio1.7×+0.3×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromLongTermLinesOfCredit.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's proceeds from long term lines of credit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bioventus's proceeds from long term lines of credit?
Bioventus (BVS) reported proceeds from long term lines of credit of $0 in Q1 2026.
How has Bioventus's proceeds from long term lines of credit changed year-over-year?
Bioventus's proceeds from long term lines of credit decreased by 100.0% year-over-year, from $15M to $0.
What does proceeds from long term lines of credit mean?
Represents the total cash inflows derived from drawing down on long-term revolving credit facilities or debt lines. It reflects the company's reliance on external financing to manage liquidity needs or fund operational requirements.